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The political and economic climate that exists today is a challenging
one for the pharmaceutical industry. To eectively compete in
today’s marketplace, companies must discover and develop truly
innovative medicines. The R&D organizations within these
companies are under increasing pressure to hold down costs while
accomplishing this mission. In this environment of level head count
and operating budgets, it is imperative that laboratory management
uses resources in the most eective, eicient ways possible. Investment
in laboratory automation is a proven tool for doing just that.
This paper looks at the strategy and tactics behind the formation
and evolution ofa central automation/laboratory technology support
function at the Glaxo Research Institute. Staffing of the function
is explained, along with operating strategy and alignment with
the scientific client base. Using the S-curve model of techno-
logicalprogress, both the realized andpotential impact on successful
R&D automation and laboratory technology development are
assessed.
Introduction
These are challenging times in the pharmaceutical
industry. The current debate over the rising cost of health
care taking place in Washington, D.C. and around the
globe has made the industry a key target for cost reduction
initiatives. Glaxo has maintained a highly proactive
strategy to discover and develop innovative medicines,
while realizing that the value of such medicines must be
demonstrated in a concrete manner. The customer base
is rapidly changing from the individual physician to a
managed care environment where price must be justified.
Coupled with this innovation strategy is a concerted effort
to find ways to reduce R&D costs and increase speed to
market by utilizing resources more effectively and
efficiently.
Laboratory managers have long realized that the effective
utilization of scientific staff meant freeing them from
repetitive, boring tasks and funneling their energies
toward more creative activities. Key to this has been the
utilization ofmodern laboratory automation and robotics.
Full implementation of the automation strategy, while
successful in many companies, often falters due to the lack
of necessary technical support in areas where most
scientists have little or no training or experience. This
is where the internal automation/laboratory technology
support function, such as the Bioengineering group within
the Glaxo Research Institute (GRI), plays a key role.
’l’his paper was presented at the 1994 ISLAR meeting.
The S-curve model
The S-curve model [1] (figure 1) is a simple yet effective
tool for charting technological progress. The horizontal
axis represents resources such as time, money, and staffing
levels while the vertical axis represents the performance
achieved by allocating these resources. Performance
may be measured in terms such as reduction in testing
costs, laboratory throughput, or re-deployment of staff,
depending on the particular area of interest. Using this
model, it is possible to graphically represent important
segments of the automation development process such as
learning, the point of diminishing returns, and the
emergence of discontinuities. Discontinuities occur when
the old technology has been fully optimized and the
progressive laboratory must look to emerging technologies
to continue improving its operating performance.
In addition to serving as a charting tool to track progress,
the S-curve may be used as a forecasting tool that allows
the laboratory to proactively manage its decisions to invest
in new technologies. Proactive decisions in the automation/
laboratory technology arena give the laboratory the
ability to maintain the productivity afforded by existing
systems while allocating a reasonable portion of its
resources to developing new ones.
It is obvious from the shape of the S-curve that the goal
of the laboratory should be to minimize the length of the
lower and upper flat portions ofthe curve and to maximize
both the slope and length of the middle portion. A
fully effective automation/laboratory technology support
function such as GR! Bioengineering is key to achieving
this overall goal.
Discussion
The GRI Bioengineering function can trace its origin to
a similar function which has existed within Glaxo
Research and Development (GRD) in the UK for more
than 20 years. The Bioengineering function exists to
support laboratory operations in the areas of automation,
laboratory technology, and instrument control and
support. The name Bioengineering is derived from the
Biological Engineering Society, a professional organ-
ization in the UK and was adopted in the USA for the
sake ofcontinuity and because it gave the function a sense
of history.
The organizational placement of the Bioengineering
function within GRI (figure 2) is critical to its function.
Though having formal reporting responsibility to the
R&D Services department within GRI Development, the
function maintains the necessary autonomy to function as
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a true Glaxo resource, fully supporting the Research and
Medical divisions of GRI and providing support to
divisions outside GRI as well. It is only through this scope
of responsibility that the staffing and resources required
to achieve ’critical mass’ can be fully justified and
effectively utilized.
The past
The GRI Bioengineering function began in 1990 as a four
member group consisting of a supervisor, two engineers,
and a design machinist. Facilities were minimal and
project management, tbr all practical purposes, was
nonexistent. Even at this early stage Bioengineering had
a positive effect on productivity in the laboratories. For
the first time, researchers had an internal resource to
support their non routine instrument needs. The success
of the group and the value it added to the GRI mission
was limited, however, by the fact that few people knew
about and were utilizing the group and those who did
were hesitant to share this newly discovered resource. GRI
Bioengineering was, for all intents and purposes, a
’servant’ organization as depicted in figure 3. As a servant
organization, the value added by the function was limited
to the projects brought forth by the scientist customers.
There was no initiative on the part of the function to
investigate and bring forth new technologies. Innovation
remained the sole responsibility of the customer. Yet,
as stagnant as the GRI Bioengineering function was
technologically, the real danger to the long term success
of the function lay in the lack of systems for project
management and documentation. Without supporting
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evidence, the case for continued and expanded resources
was seriously lacking.
The present
In 1992, the GRI Bioengineering function began taking
on a new look and a new focus. First, the function was
split into two separate groups: Instrument Control and
Advanced Design and Automation. I was recognized that
to fully support the laboratory technology needs of an
R&D organization as complex as GRI, separate special-
ized functions were needed. Instrument Control has as its
mission the comprehensive management of laboratory
instrumentation and related systems including service and
maintenance, vendor contracts, and calibration. The
Advanced Design and Automation section is charged with
designing, developing, and prototyping novel instruments
and automated systems to support innovative R&D
initiatives. With a total staff of 15 people and state-of-
the-art mechanical design, electronic design, and metrology
laboratories, these two sections are no longer merely
servant organizations but highly proactive technical
service organizations (figure 3) that formulate innovative
solutions to highly complex scientific problems. Formal
project and data management has been implemented
through the use of advanced software tools providing
critical justification for resources and maintaining docu-
mentation needed for project management and regulatory
purposes. The GRI Bioengineering function now actively
pursues and implements new technologies as needed to
support the GRI scientific community.
The fulure
The key to the future for the GRI Bioengineering function
is to make the final leap from service organization to full
scientific partner as depicted in figure 3. The effectiveness
ofthe function is optimized under this relationship because
no longer is GRI Bioengineering in a reactive or
semi-reactive mode of operation but is almost entirely
proactive. At the partnership level, strategies and ideas
are openly shared between the laboratory technology
support group and the client laboratory. This dialogue is
conducive to the development ofexpedient and innovative
solutions to even highly complex problems.
The key challenges facing GRI Bioengineering lie both
outside and inside of the organization. Laboratory groups
may be reluctant to share sensitive technical problems
with internal groups outside their immediate organ-
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customer interaction and consulting skills in addition to
their recognized technical skills.
Being involved as a full partner with its GRI customer
base at the strategic and tactical planning level will allow
GRI Bioengineering to more fully meet and exceed the
needs of its clients on a regular basis.
Critical success factors
Of the many factors that in one way or another impact
the success of the laboratory technology and automation
support function, four have been identified as being
absolutely critical. These include management commit-
ment and support, organization and staffing, operating
strategy and tactics, and marketing ofservices. As detailed
below, each of these factors plays an important role in
shaping the function and directly determine its value to
the organization.
Management commitment and support
Management commitment and support is important to
the success of any function. In the case of the laboratory
technology and automation support function, this support
is especially critical to its success. The pharmaceutical
R&D organization centres its activities around the
discovery and development of specific compounds identified
as having therapeutic value. The laboratory technology
and automation support function must compete with the
laboratory functions directly involved with these com-
pounds for available, finite resources. To be successful,
the laboratory technology and automation support
thnction is dependent on management that thinks
strategically and takes the long view. Rarely, if ever, are
the benefits of such a function immediate. It is only over
time that the true benefits are realized through the
development of innovative instruments and systems that
save time and money and facilitate novel experimentation
by the scientific staff. It is easy to be overlooked in the
battle tbr resources so the laboratory technology and
automation support function must remain a visible and
technologically proactive organization. Documentation of
successes and effective utilization of resources through
sound project management are key to maintaining strong
management commitment and support.
Organization and sta2fng
The organization and staffing ofthe laboratory technology
and automation support function must be in complete
alignment with its strategic objectives. To be fully
effective, the function must incorporate a variety of skill
sets (figure 4) acting together as a team. Staffing should
incorporate the scientific and engineering disciplines
and the skilled trades, such as design machinists and
draftsmen. It is difficult to describe a major system
development project that does not have significant
mechanical and electronic design components. The
scientific components must be added to this to ensure that
the resulting system will function in the laboratory, and,
of course, someone must actually make non-commercially
available parts and assemble the final system.
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Operating strategy and tactics
A clearly defined, easily understood operating strategy
must be formulated and adhered to by the successful
laboratory technology and automation support function.
Within GRI Bioengineering this strategy takes the form
of a mission statement. The Advanced Design and
Automation section has the following mission statement:
Our mission is to support innovative R&D by designing,
building, or recommending novel scientific devices and equipment
based upon state-of-the-art methods and technologies to solve
problems and automate processes in the laboratory. Our primary
focus is on prototyping new devices and systems which are not
commercially available.
Of course the real value of any mission statement is how
well the organization actually adheres to it. It is critical
that the organization avoid falling victim to the ’not
invented here’ syndrome and end up making devices
and components that are commercially available. In
fact, finding and recommending commercially available
solutions is one of the most important ways that the
laboratory technology and automation support function
adds value to the R&D organization. Constant bench-
marking against vendors and peer companies is important
to ensure the competitive value ofthe function. Tactically,
it is critical that the laboratory technology and automation
support function manage its projects in such a way that
customer expectations are met (figure 5). Put simply,
’Establish realistic timelines and meet them/’ It has been the
experience of the GRI Bioengineering function that
projects extending greater than three months often
become irrelevant. It is important to know the limits of
the function and employ strategic outsourcing as needed
to bring projects to completion in a timely manner.
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Finally, it is important to note the word prototyping in the
Advanced Design and Automation mission statement. A
fully developed and tested prototype should trigger efforts
to outsource the production model of a particular device
or system. With full drawings and specifications available,
it is a relatively simple matter to accomplish this, leaving
the laboratory technology and automation support
function free to focus on the next problem.
Marketing of services
The concept of marketing is not often associated with the
laboratory technology and automation support function,
but it is critical to its long-term effectiveness and ultimate
success. Marketing in this sense means making the
scientific client base aware of the function and its
capabilities. Doing so ensures that the function will have
broad exposure to problems across the R&D organization
that may determine technology and accompanying staff
development initiatives. The overall goal of the marketing
effort is to increase the quality and strategic importance
ofthe projects taken on, not the quantity ofwork performed.
Applying the S-curve model
The S-curve model is an effective tool for tracking and
forecasting technological progress. The model is readily
applied to the area of laboratory robotics, as shown in
figure 6. In this example, key areas of the S-curve depict
stages in the life of a newly purchased laboratory robot.
The first stage, when the robot is purchased, represents
learning. During this stage, resources are expended both
to purchase the robol and to train its operator(s) with
little performance gain to the laboratory. The second
stage, when modifications are made and custom modules
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Figure 6. Applying the S-curve model.
are built, represents maximum return on investment by
the laboratory. During this stage each dollar spent results
in significant gains in performance. The third stage
represents a fully optimized system and further expenditure
of resources results in diminishing gains in performance.
As the upper portion of the S-curve flattens, the robot
becomes a legacy system and has reached its technological
potential. It is at this point that a discontinuity becomes
apparent between the existing technology and emerging
technology. In the case of robotic systems, this emerging
technology may take the form of vision systems, artificial
intelligence, or advanced electronics such as fuzzy logic,
depending on the particular application. In any case, it
is important that the laboratory recognize this discontinuity
and manage its resources in such a manner that the
emerging technology can be exploited.
The laboratory technology and automation support
function is an important resource for helping the laboratory
chart its course along the S-curve. Through its design and
prototyping capabilities, the function may facilitate the
move up the steep portion ofthe curve while its knowledge
of state-of-the-art technologies can help the laboratory
anticipate and effectively manage the discontinuities.
Conclusion
This paper has detailed the stragegy and tactics behind
the formation and evolution of a central laboratory
technology and support thnction at the Glaxo Research
Institute. The S-curve model was demonstrated to be an
effective tool for tracking and forecasting technological
advancement. If there is a weakness in this model, it is
that the model is deceptively simple. Moving up the
S-curve requires sound strategic planning and plenty of
hard work. The laboratory technology and support
function, when optimally organized and managed, can
be a key facilitator in this process.
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